75 results
8-K
EX-99.1
DNLI
Denali Therapeutics Inc
27 Feb 24
Denali Therapeutics Announces $500 million Private Placement Equity Financing
8:03am
Transport Vehicle (TV) technology, as well as general corporate purposes and working capital.
The financing was led by a U.S.-based healthcare-focused
8-K
EX-99.1
DNLI
Denali Therapeutics Inc
8 Jan 24
Regulation FD Disclosure
8:06am
a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, at 10:30 a.m. Pacific Time.
“In 2024, we expect … inhibitor)
Continue Phase 2 UC study
Sanofi
Webcast and slide deck for Denali’s corporate presentation at the J.P. Morgan Healthcare Conference
8-K
DNLI
Denali Therapeutics Inc
8 Jan 24
Regulation FD Disclosure
8:06am
and expected milestones for 2024 and the Company’s participation in the 42st Annual J.P. Morgan Healthcare Conference.
A copy of the press release
8-K
EX-99.1
4pkq62
7 Nov 23
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
4:04pm
8-K
EX-99.1
n7pi13
8 Aug 23
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
4:04pm
8-K
EX-99.1
kfgmn
8 May 23
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
4:03pm
8-K
EX-99.1
fl4808y97bkd
3 Nov 22
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
4:05pm
8-K
EX-99.1
h5lm d8xqzq5ax
20 Oct 22
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
4:58pm
8-K
EX-1.1
oewf3g ohkgn
20 Oct 22
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
4:58pm
424B5
68l53swwv1r5d2j
20 Oct 22
Prospectus supplement for primary offering
4:57pm
8-K
EX-99.1
t7f89ggwvd6nom
18 Oct 22
Denali Therapeutics Announces Proposed Offering of Common Stock
5:09pm
8-K
EX-99.3
1x82gmc
18 Oct 22
Denali Therapeutics Announces Proposed Offering of Common Stock
5:09pm
424B5
33nwxz
18 Oct 22
Prospectus supplement for primary offering
5:08pm